|
1
|
Venook AP, Papandreou C, Furuse J and de
Guevara LL: The incidence and epidemiology of hepatocellular
carcinoma: a global and regional perspective. Oncologist. 15(Suppl
4): 5–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar
|
|
6
|
Liu L, Cao Y, Chen C, et al: Sorafenib
blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and
induces tumor cell apoptosis in hepatocellular carcinoma model
PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gu FM, Li QL, Gao Q, et al: Sorafenib
inhibits growth and metastasis of hepatocellular carcinoma by
blocking STAT3. World J Gastroenterol. 17:3922–3932. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng AL, Kang YK, Chen Z, et al: Efficacy
and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.
2009. View Article : Google Scholar
|
|
10
|
Roy M, Luo YH, Ye M and Liu J: Nonsmall
cell lung cancer therapy: insight into multitargeted small-molecule
growth factor receptor inhibitors. Biomed Res Int.
2013:9647432013.PubMed/NCBI
|
|
11
|
Nojiri K, Sugimoto K, Shiraki K, et al:
Sorafenib and TRAIL have synergistic effect on hepatocellular
carcinoma. Int J Oncol. 42:101–108. 2013.PubMed/NCBI
|
|
12
|
Schmieder R, Puehler F, Neuhaus R, et al:
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in
combination with sorafenib exhibits antitumor activity in
preclinical murine and rat models of hepatocellular carcinoma.
Neoplasia. 15:1161–1171. 2013.
|
|
13
|
Hoffmann K, Glimm H, Radeleff B, et al:
Prospective, randomized, double-blind, multi-center, phase III
clinical study on transarterial chemoembolization (TACE) combined
with Sorafenib versus TACE plus placebo in patients with
hepatocellular cancer before liver transplantation - HeiLivCa
[ISRCTN24081794]. BMC Cancer. 8:3492008.PubMed/NCBI
|
|
14
|
Abou-Alfa GK, Johnson P, Knox JJ, et al:
Doxorubicin plus sorafenib vs doxorubicin alone in patients with
advanced hepatocellular carcinoma: a randomized trial. JAMA.
304:2154–2160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hsu CH, Shen YC, Lin ZZ, et al: Phase II
study of combining sorafenib with metronomic tegafur/uracil for
advanced hepatocellular carcinoma. J Hepatol. 53:126–131. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR,
Bhagat N and Geschwind JF: Phase II trial of sorafenib combined
with concurrent transarterial chemoembolization with drug-eluting
beads for hepatocellular carcinoma. J Clin Oncol. 29:3960–3967.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cabrera R, Pannu DS, Caridi J, et al: The
combination of sorafenib with transarterial chemoembolisation for
hepatocellular carcinoma. Aliment Pharmacol Ther. 34:205–213. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Petrini I, Lencioni M, Ricasoli M, et al:
Phase II trial of sorafenib in combination with 5-fluorouracil
infusion in advanced hepatocellular carcinoma. Cancer Chemother
Pharmacol. 69:773–780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mochizuki S and Okada Y: ADAMs in cancer
cell proliferation and progression. Cancer Sci. 98:621–628. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and
Tao HQ: ADAM 10 is associated with gastric cancer progression and
prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee SB, Schramme A, Doberstein K, et al:
ADAM10 is upregulated in melanoma metastasis compared with primary
melanoma. J Invest Dermatol. 130:763–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang W, Liu S, Liu K, et al: A
disintegrin and metalloprotease (ADAM)10 is highly expressed in
hepatocellular carcinoma and is associated with tumour progression.
J Int Med Res. 42:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yue Y, Shao Y, Luo Q, Shi L and Wang Z:
Downregulation of ADAM10 expression inhibits metastasis and
invasiveness of human hepatocellular carcinoma HepG2 cells. Biomed
Res Int. 2013:4345612013.PubMed/NCBI
|
|
24
|
Yang CL, Jiang FQ, Xu F and Jiang GX:
ADAM10 overexpression confers resistance to doxorubicin-induced
apoptosis in hepatocellular carcinoma. Tumour Biol. 33:1535–1541.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brummelkamp TR, Bernards R and Agami R: A
system for stable expression of short interfering RNAs in mammalian
cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Li Z and Wang K: Combining
sorafenib with celecoxib synergistically inhibits tumor growth of
non-small cell lung cancer cells in vitro and in
vivo. Oncol Rep. 31:1954–1960. 2014.PubMed/NCBI
|
|
27
|
Gagnon V, Van Themsche C, Turner S,
Leblanc V and Asselin E: Akt and XIAP regulate the sensitivity of
human uterine cancer cells to cisplatin, doxorubicin and taxol.
Apoptosis. 13:259–271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chekenya M, Krakstad C, Svendsen A, et al:
The progenitor cell marker NG2/MPG promotes chemoresistance by
activation of integrin-dependent PI3K/Akt signaling. Oncogene.
27:5182–5194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McDonald GT, Sullivan R, Paré GC and
Graham CH: Inhibition of phosphatidylinositol 3-kinase promotes
tumor cell resistance to chemotherapeutic agents via a mechanism
involving delay in cell cycle progression. Exp Cell Res.
316:3197–3206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Benson AB III, Abrams TA, Ben-Josef E, et
al: NCCN clinical practice guidelines in oncology: hepatobiliary
cancers. J Natl Compr Canc Netw. 7:350–391. 2009.PubMed/NCBI
|
|
31
|
Klein T and Bischoff R: Active
metalloproteases of the a disintegrin and metalloprotease (ADAM)
family: biological function and structure. J Proteome Res.
10:17–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seals DF and Courtneidge SA: The ADAMs
family of metalloproteases: multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao H, Zhu J, Cui K, et al:
Bioluminescence imaging reveals inhibition of tumor cell
proliferation by Alzheimer’s amyloid β protein. Cancer Cell Int.
9:152009.PubMed/NCBI
|
|
34
|
Endres K and Fahrenholz F: Upregulation of
the α-secretase ADAM10 - risk or reason for hope? FEBS J.
277:1585–1596. 2010.
|
|
35
|
Lin T, Gu J, Zhang L, et al: Enhancing
adenovirus-mediated gene transfer in vitro and in vivo by addition
of protamine and hydrocortisone. J Gene Med. 5:868–875. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Emdad L, Lebedeva IV, Su ZZ, et al:
Combinatorial treatment of non-small-cell lung cancers with
gefitinib and Ad. mda-7 enhances apoptosis-induction and
reverses resistance to a single therapy. J Cell Physiol.
210:549–559. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bai S, Nasser MW, Wang B, et al:
MicroRNA-122 inhibits tumorigenic properties of hepatocellular
carcinoma cells and sensitizes these cells to sorafenib. J Biol
Chem. 284:32015–32027. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McCubrey JA, Sokolosky ML, Lehmann BD, et
al: Alteration of Akt activity increases chemotherapeutic drug and
hormonal resistance in breast cancer yet confers an achilles heel
by sensitization to targeted therapy. Adv Enzyme Regul. 48:113–135.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kunter I, Erdal E, Nart D, et al: Active
form of AKT controls cell proliferation and response to apoptosis
in hepatocellular carcinoma. Oncol Rep. 31:573–580. 2014.PubMed/NCBI
|
|
40
|
Chiablaem K, Lirdprapamongkol K,
Keeratichamroen S, Surarit R and Svasti J: Curcumin suppresses
vasculogenic mimicry capacity of hepatocellular carcinoma cells
through STAT3 and PI3K/AKT inhibition. Anticancer Res.
34:1857–1864. 2014.PubMed/NCBI
|
|
41
|
Xiu P, Xu Z, Liu F, et al: Downregulating
sCLU enhances the sensitivity of hepatocellular carcinoma cells to
gemcitabine by activating the intrinsic apoptosis pathway. Dig Dis
Sci. Mar 27–2014.(Epub ahead of print).
|
|
42
|
Edling CE, Selvaggi F, Ghonaim R, Maffucci
T and Falasca M: Caffeine and the analog CGS 15943 inhibit cancer
cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.
Cancer Biol Ther. 15:524–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
